Showing 1 - 20 results of 22 for search 'Mary L Disis', query time: 0.06s
Refine Results
-
1
Clinical significance of tumor-infiltrating lymphocytes in breast cancer by Mary L. Disis, Sasha E. Stanton
Published 2016-11-01
Article -
2
Vaccines for cancer interception in familial adenomatous polyposis by David E. Johnson, Mary L. Disis
Published 2025-01-01
Article -
3
Mac Cheever (1944–2021): a tribute to a life of achievement and service by Philip D Greenberg, Mary L Disis, Kim A Margolin, Paul M Sondel, Lynn M Matrisian
Published 2022-01-01
Article -
4
834 Retinoid X receptor agonists enhances type I systemic and intratumoral immunity, but enhanced tumor prevention, with the HER2-IGFBP2-IGF1R plasmid vaccine in two mouse mammary... by Mary L Disis, Sasha E Stanton, Shizuko Sei, Lauren Corulli, Rodmaker Erin, Nicholas Drovetto, Venkatram Atigadda, Clinton Grubbs
Published 2023-11-01Article -
5
-
6
-
7
-
8
-
9
Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients by Sasha E. Stanton, Ekram Gad, Erik Ramos, Lauren Corulli, James Annis, Jennifer Childs, Hiroyuki Katayama, Samir Hanash, Jeffrey Marks, Mary L. Disis
Published 2021-05-01
Article -
10
-
11
Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo by Yushe Dang, Jennifer Childs, Doreen Higgins, Sasha E. Stanton, Janet F. Eary, Edmond A. Marzbani, David Mankoff, Lupe G. Salazar, Jessica Reichow, Mary L. Disis
Published 2016-06-01
Article -
12
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art by Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, David R. Kaufman, Samir N. Khleif, Ena Wang, on behalf of the Society for Immunotherapy of Cancer Immuno-Oncology Biomarkers: State of the Art workshop speakers
Published 2018-12-01
Article -
13
Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response by Mary L Disis, John B Liao, Jessica L Reichow, Lupe G Salazar, Sasha E Stanton, Katie M Hitchcock-Bernhardt, James Y Dai, Jong-Baeck Lim, Theodore A Gooley
Published 2024-11-01
Article -
14
A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer by William R. Gwin, Lupe G. Salazar, James Y. Dai, Doreen Higgins, Andrew L. Coveler, Jennifer S. Childs, Rosie Blancas, Yushe Dang, Jessica Reichow, Meredith Slota, Hailing Lu, Mary L. Disis
Published 2025-01-01
Article -
15
163 A multi-modal, pan-cancer atlas of tumor-immune states across primary and metastatic disease using a large, real-world database by Mary L Disis, Justin Guinney, Kate Sasser, Rohan Joshi, Paul Fields, Ariane Lozac’hmeur, Prerna Jain, Luca Lonini, Martin Stumpe, Michelle M Stein, Halla Nimeiri, Bolesław Osinski, Catherine Igartua
Published 2023-11-01Article -
16
-
17
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy by Amrita Basu, Ganesan Ramamoorthi, Gabriella Albert, Corey Gallen, Amber Beyer, Colin Snyder, Gary Koski, Mary L. Disis, Brian J. Czerniecki, Brian J. Czerniecki, Brian J. Czerniecki, Krithika Kodumudi, Krithika Kodumudi
Published 2021-05-01
Article -
18
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy by Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus O. Butler, Mary L. Disis, Jérôme Galon, Leif G. Hakansson, Brent A. Hanks, Vaios Karanikas, Samir N. Khleif, John M. Kirkwood, Lance D. Miller, Dolores J. Schendel, Isabelle Tanneau, Jon M. Wigginton, Lisa H. Butterfield
Published 2017-05-01
Article -
19
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer by Anne Mills, Leisha A Emens, Mary L Disis, Kunle Odunsi, John B Liao, Tyler Curiel, Margaret Gatti-Mays, Amir Jazaeri, Emese Zsiros, Marcus O Butler, Jyoti Bajpai, Katherine C Kurnit, Haider Mahdi, Laura Doherty, Claire F Friedman, Melissa A Geller, Sarah F Adams, Shelley A Dodt, Veena S John
Published 2023-06-01
Article -
20
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates by Mary L Disis, John B Liao, Doreen M Higgins, Jennifer S Childs, Sasha E Stanton, Anna V Tinker, William R Gwin, Renata R Urban, Katie M Hitchcock-Bernhardt, Andrew L Coveler, Hania N Shakalia, Ron E Swensen, Tanya A Wahl, Richard G Ancheta, Kathryn F McGonigle, James Y Dai, Barbara A Goff
Published 2021-09-01
Article